Vaxcyte, INC

Vaxcyte, Inc. reports the retirement of Heath Lukatch from its Board of Directors and the appointment of John Markels as a new Class II director.

Vaxcyte, Inc. held its Annual Meeting of Stockholders on June 15, 2026, where key directors were re-elected and the appointment of Deloitte & Touche LLP as auditor was ratified.

Vaxcyte, Inc. has established a new 'at-the-market' equity offering program to sell up to $500 million of its common stock through Leerink Partners LLC.

Vaxcyte, Inc. announced its Q4 and full-year 2025 financial results, highlighting significant progress in its VAX-31 adult and infant clinical programs, manufacturing readiness, and a recent $600 million equity offering.

Vaxcyte, Inc. successfully completed a public offering of 12.65 million common shares, including the full exercise of an over-allotment option, generating approximately $600.2 million in net proceeds.

Vaxcyte, Inc. has amended its executive change in control and severance agreements, increasing severance multipliers for its CEO and other key officers to align with peer group levels.

Vaxcyte reports a significant increase in R&D expenses for Q1 2026, driven by advancements in its PCV franchise, while maintaining a robust cash and investment balance.

Vaxcyte reports increased net losses in Q3 2025 and for the nine months ended September 30, 2025, while advancing its broad-spectrum pneumococcal conjugate vaccine (PCV) candidates and securing long-term manufacturing agreements.

Vaxcyte, a clinical-stage vaccine company, reported increased net losses in Q2 2025 while strategically advancing its lead pneumococcal conjugate vaccine candidates and streamlining its early-stage pipeline.

Vaxcyte announces positive topline results from its VAX-24 infant Phase 2 dose-finding study and progresses its VAX-31 infant Phase 2 study to the final stage.

Vaxcyte's Q3 2024 filing highlights positive clinical trial results for VAX-31, a significant capital raise, and ongoing development of its vaccine pipeline.

Vaxcyte, a clinical-stage vaccine company, reported a net loss of $128.7 million for the second quarter of 2024, while advancing its pipeline of vaccine candidates.

Vaxcyte initiated multiple Phase 3 trials for its 31-valent pneumococcal vaccine candidate, VAX-31, following positive Phase 1/2 results and expanded Breakthrough Therapy Designation, while also raising $632.5 million in a public offering.

Vaxcyte reports positive clinical trial results and progresses its vaccine pipeline, including a breakthrough therapy designation for VAX-31.

Vaxcyte has entered into a significant manufacturing agreement with Lonza, securing a dedicated suite for production and gaining control over a crucial supply chain element.

Harpreet S. Dhaliwal, Chief Technical Ops Officer of Vaxcyte, Inc., sold 17,000 shares of common stock on August 5, 2026 for $55.00 per share.

Jim Wassil, CHIEF OPERATING OFFICER of Vaxcyte, Inc., sold 2,250 shares of common stock on August 3, 2026.

Andrew Guggenhime, PRESIDENT AND CFO of Vaxcyte, Inc., sold 10,000 shares of common stock on August 3, 2026.

Grant Pickering, CHIEF EXECUTIVE OFFICER and a Director of Vaxcyte, Inc., sold 18,198 shares of common stock on July 27, 2026.

John Markels, a Director of Vaxcyte, Inc., received 23,029 shares of common stock on July 16, 2026.

Vaxcyte, Inc. reports that President and CFO Andrew Guggenhime sold 10,000 shares of common stock under a pre-arranged trading plan.

Vaxcyte, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 15, 2026, to elect directors, ratify auditors, and vote on executive compensation.

Vaxcyte, Inc. announces its 2025 Annual Meeting of Stockholders to be held on June 12, 2025, outlining proposals for director elections, auditor ratification, executive compensation approval, and certificate of incorporation amendment.

Vaxcyte, Inc. announces its 2025 Annual Meeting of Stockholders to vote on director elections, auditor ratification, executive compensation, and an amendment for officer exculpation.

Vaxcyte, Inc. announces its 2024 Annual Meeting of Stockholders to be held on June 6, 2024, outlining key proposals for voting, including the election of directors and ratification of the company's accounting firm.

Vaxcyte's upcoming Annual Meeting of Stockholders on June 6, 2024, will address the election of directors, ratification of the independent auditor, and an advisory vote on executive compensation.

Janus Henderson Group Ltd. has updated its beneficial ownership filing for Vaxcyte, Inc., reporting a 12.1% stake.

Janus Henderson Group Ltd. has filed an amendment to its Schedule 13G, reporting a decrease in its beneficial ownership of Vaxcyte, Inc. common stock.

RA Capital Management and its principals have reported an 8.9% beneficial ownership stake in Vaxcyte, Inc. as of March 31, 2026.

Janus Henderson Group plc has reported beneficial ownership of 16,575,875 shares, representing 11.5% of Vaxcyte, Inc.'s common stock as of March 31, 2026.

FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 11.4% of Vaxcyte Inc.'s common stock as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.03% of Vaxcyte Inc.'s common stock as of March 31, 2026.